Video

Dr. Iyer on Erdafitinib-Related Hyperphosphatemia in Metastatic Urothelial Cancer

Author(s):

Gopa Iyer, MD, discusses treatment-emergent hyperphosphatemia with erdafitinib in patients with metastatic urothelial cancer.

Gopa Iyer, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment-emergent hyperphosphatemia with erdafitinib (Balversa) in patients with metastatic urothelial cancer.

In April 2019, the FDA granted accelerated approval to erdafitinib for the treatment of patients with locally advanced or metastatic urothelial cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy.

FGFR inhibitors like erdafitinib appear to increase phosphorus reabsorption in the body and lead to hyperphosphatemia, explains Iyer.

Generally, hyperphosphatemia can be controlled with dietary changes such as reducing dairy and meat intake and adding oral phosphate binders like sevelamer (Renagel), says Iyer.

Notably, phosphate levels indicate response to erdafitinib, says Iyer. The FDA designation recommends starting patients on erdafitinib at a daily dose of 8 mg. If a patient’s phosphate level is <5.5 mg/dL after 2 to 3 weeks of treatment, the dose should be increased to 9 mg once daily to increase FGFR inhibition.

Related Videos
Roger Li, MD, of Moffitt Cancer Center
Michael Deininger, MD, PhD
Shubham Pant, MD, MBBS
Kedar Kirtane, MD
Mazyar Shadman, MD, MPH
Allison Winter, MD, Department of Hematology and Medical Oncology, Cleveland Clinic
Malcolm Mattes, MD, associate professor, Section of Radiation Oncology, Rutgers Robert Wood Johnson Medical School; radiation oncologist, Rutgers Cancer Institute of New Jersey
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology